selected publications
- Gut bacteria-derived serotonin promotes immune tolerance in early life. Science immunology. 2024 Academic Article GET IT
- Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer letters. 2024 Academic Article GET IT
- Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. 2023 GET IT
- Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection. Gut microbes. 2022 Academic Article GET IT
- Extracellular Matrix in Synthetic Hydrogel-based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 inhibitors. Advanced materials (Deerfield Beach, Fla.). 2021 Academic Article GET IT
-
Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition.
International journal of oncology.
2020
Academic Article
GET IT
Times cited: 13 -
In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells.
Oncology reports.
2017
Academic Article
GET IT
Times cited: 5 -
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.
Frontiers in immunology.
2015
Information Resource
GET IT
Times cited: 45